Header cover image

Taiwanese (TAIEX) Clinical Research and Equipment Industry Analysis

UpdatedJan 30, 2025
DataAggregated Company Financials
Companies9
  • 7D0%
  • 3M-13.0%
  • 1Y-15.7%
  • YTDn/a

The Clinical Research and Equipment industry is up 3.7% in the last week, with EirGenix up 5.5%. However, the industry is down 15% over the past year. Earnings are forecast to grow by 40% annually.

Industry Valuation and Performance

Has the Taiwanese Clinical Research and Equipment Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 30 Jan 2025NT$36.8bNT$2.6b-NT$854,432,000.0023.5x-43.1x14.4x
Sat, 28 Dec 2024NT$34.2bNT$2.6b-NT$854,432,000.0023.3x-40x13.3x
Mon, 25 Nov 2024NT$40.6bNT$2.6b-NT$854,432,000.0024x-47.5x15.8x
Wed, 23 Oct 2024NT$41.1bNT$2.3b-NT$836,610,000.0022.5x-49.1x18.1x
Fri, 20 Sep 2024NT$42.0bNT$2.3b-NT$836,610,000.0022.1x-50.2x18.5x
Sun, 18 Aug 2024NT$40.8bNT$2.3b-NT$825,450,000.0020.1x-49.5x18.1x
Tue, 16 Jul 2024NT$44.5bNT$2.1b-NT$797,765,000.0033.8x-55.8x20.9x
Thu, 13 Jun 2024NT$42.4bNT$2.1b-NT$797,765,000.0032.8x-53.2x19.9x
Sat, 11 May 2024NT$39.9bNT$2.1b-NT$914,899,000.0032.2x-43.6x18.8x
Mon, 08 Apr 2024NT$40.0bNT$2.1b-NT$903,875,000.0031.6x-44.3x19x
Wed, 06 Mar 2024NT$42.8bNT$2.1b-NT$611,249,000.0033.4x-69.9x20.7x
Fri, 02 Feb 2024NT$43.5bNT$2.1b-NT$610,218,000.0033.3x-71.3x21x
Sun, 31 Dec 2023NT$47.8bNT$2.1b-NT$610,218,000.0033.3x-78.4x23x
Tue, 28 Nov 2023NT$49.6bNT$2.1b-NT$610,218,000.0033.6x-81.3x23.9x
Thu, 26 Oct 2023NT$49.3bNT$2.2b-NT$497,769,000.0031.2x-99x22.1x
Sat, 23 Sep 2023NT$44.1bNT$2.2b-NT$497,769,000.0031.5x-88.5x19.8x
Mon, 21 Aug 2023NT$43.3bNT$2.2b-NT$497,769,000.0031.1x-86.9x19.4x
Wed, 19 Jul 2023NT$47.5bNT$2.5b-NT$274,767,000.0042.6x-172.9x19.4x
Fri, 16 Jun 2023NT$48.4bNT$2.5b-NT$274,767,000.0043.7x-176.2x19.7x
Sun, 14 May 2023NT$49.0bNT$2.7b-NT$29,017,000.0023.4x-1689.5x18.4x
Tue, 11 Apr 2023NT$51.5bNT$2.7b-NT$29,761,000.0024.5x-1729.7x19.4x
Thu, 09 Mar 2023NT$49.3bNT$2.7bNT$82.4m25.5x598.7x18.6x
Sat, 04 Feb 2023NT$50.4bNT$2.7bNT$85.3m19.5x590.9x18.8x
Mon, 02 Jan 2023NT$49.8bNT$2.7bNT$85.3m18.9x583.8x18.6x
Wed, 30 Nov 2022NT$52.1bNT$2.7bNT$139.5m18.6x373.2x19.5x
Fri, 28 Oct 2022NT$42.1bNT$3.0bNT$482.8m23.9x87.1x14.1x
Sun, 25 Sep 2022NT$45.5bNT$3.0bNT$482.8m25.3x94.2x15.2x
Tue, 23 Aug 2022NT$44.5bNT$3.0bNT$498.3m27.7x89.2x14.6x
Thu, 21 Jul 2022NT$38.6bNT$3.1bNT$325.1m37.4x118.7x12.6x
Sat, 18 Jun 2022NT$40.5bNT$3.1bNT$325.1m36.3x124.7x13.2x
Mon, 16 May 2022NT$29.5bNT$2.9bNT$80.8m26.8x364.9x10.1x
Wed, 13 Apr 2022NT$35.9bNT$3.2bNT$164.4m27.8x218.4x11.3x
Fri, 11 Mar 2022NT$33.3bNT$3.0b-NT$115,919,000.0025.1x-287.5x10.9x
Sun, 06 Feb 2022NT$35.8bNT$3.0b-NT$120,147,000.0034.3x-298.1x11.8x
Price to Earnings Ratio

-298.1x


Total Market Cap: NT$35.8bTotal Earnings: -NT$120,147,000.00Total Revenue: NT$3.0bTotal Market Cap vs Earnings and Revenue0%0%0%
Taiwanese Clinical Research and Equipment Industry Price to Earnings3Y Average -71x202320242025
Current Industry PE
  • Investors are pessimistic on the Taiwanese Life Sciences Tools and Services industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The 3-year average PS ratio of 17.5x is higher than the industry's current PS ratio of 14.4x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences Tools and Services industry have deteriorated over the last three years.
  • Revenues have also declined 5.6% per year.
  • This means overall sales from these companies are declining and losses are subsequently expanding as well.

Industry Comparison

How does Taiwanese Clinical Research and Equipment compare with similar industries?

TW Market0%0
Healthcare0%0
Life Sciences0%0
Clinical Research and Equipment0%0
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
No data available
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News